BP
Basilea Pharmaceutica AG
BPMUF · OTC
$77.40 +0.00% (+$0.00)
Market Cap CHF 790.2M
P/E Ratio 19.65x
Div. Yield -
ROE 33.97%
Bulios Fair Price
$101.27
30.8% upside
Current Price
$77.4
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BPMUF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
9/9Valuation
59 /100
Fair EV/EBITDA 16.69x
P/S 3.40x
P/B 6.17x
Growth
97 /100
Growing Rev. growth 16.31%
FCF growth 151.21%
EPS growth 45.47%
Profitability
96 /100
Strong Net margin 17.30%
Op. margin 22.20%
FCF margin 25.59%
Quality
94 /100
Excellent ROE 33.97%
ROA 14.26%
Asset turnover 0.82x
Debt
77 /100
Low Current ratio 5.11x
Net debt/EBITDA 1.38x
Debt/Equity 0.79x
Stability
47 /100
Moderate Rev. volatility 13.61%
EPS volatility 351.83%
Profitable years 4
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BPMUF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Veitch
Employees
189
Headquarters
Allschwil
Upcoming events
16 FEB
Earnings
Upcoming earnings report